कंपनी का अवलोकन
NEXGEL, Inc. is a specialized manufacturer and distributor focused on high water content, electron beam cross-linked, and aqueous polymer hydrogels designed for critical applications in wound care, medical diagnostics, transdermal drug delivery, and cosmetics within the United States market. The enterprise operates strictly within the Healthcare sector, specifically targeting the Medical Instruments & Supplies industry, which implies a reliance on regulatory compliance and specialized supply chain logistics to serve both clinical and consumer needs. The company's current market capitalization stands at $4.81M, with an annual revenue of $11.42M, while the specific employee count is not disclosed in available records. These valuation and revenue figures indicate that NEXGEL, Inc. functions as a micro-cap entity with a relatively small operational footprint, suggesting limited market dominance but potentially high niche concentration in its specific hydrogel product lines.
वित्तीय स्वास्थ्य
The company reported total revenue of $11.42M over the trailing twelve months, yet it simultaneously recorded a net income loss of $3.00M and an EBITDA of $-2.902M, revealing a significant structural cost burden where expenses vastly exceed gross profitability before tax adjustments. The negative gap between revenue and net income highlights a cost structure that is currently unsustainable without substantial operational restructuring or a drastic increase in gross margins to cover fixed overheads. Free cash flow stands at $-1.75325M, which indicates that the company is burning cash reserves to fund its operations and potentially invest in research or capacity expansion, thereby limiting its immediate financial flexibility to weather market downturns. Gross margin remains positive at 39.5%, demonstrating that the core production and sales of hydrogels retain value after direct costs, whereas the operating margin of -43.4% and profit margin of -26.3% illustrate severe inefficiencies in managing administrative and selling expenses relative to revenue generation. On the balance sheet, the company holds $317,000 in cash against $3.09M in debt, resulting in a debt-to-equity ratio of 63.14, which characterizes a highly leveraged financial position where liabilities significantly outweigh equity. The current ratio of 1.47 suggests that the company possesses sufficient current assets to cover its short-term liabilities, providing a moderate buffer against immediate liquidity crises despite the overall debt burden. Return on equity is -52.7% and return on assets is -19.5%, metrics that reveal management is currently destroying shareholder value and failing to generate adequate returns on the capital base deployed for the business.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is not available due to negative earnings, but the forward P/E is calculated at 2.57, implying that the market is pricing in expectations of future profitability that are vastly different from current performance. The price-to-book ratio stands at 0.93, indicating that the stock is trading at a discount to its tangible book value, which often suggests a market undervaluation of assets or a lack of confidence in future earnings potential. The price-to-sales ratio is 0.42, and the EV/EBITDA is -2.83, both of which serve as alternative valuation metrics that suggest the company is trading at a low multiple relative to its sales, though the negative EV/EBITDA reflects the significant losses impacting enterprise value calculations. The 52-week high is $3.02 and the 52-week low is $0.58, placing the current valuation context within a wide trading range that reflects high volatility and sensitivity to market sentiment regarding the company's turnaround prospects. The beta value is not available, preventing a direct quantification of the stock's price volatility relative to the broader market, though the wide spread between the 52-week high and low inherently suggests significant price swings.
Growth & Income
Revenue growth year-over-year has contracted by -8.1%, while earnings growth is not available due to the absence of positive earnings in the prior period, indicating that the company is shrinking in terms of top-line sales rather than growing faster than its revenue base. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing income to shareholders, the entity retains all earnings—which are currently negative—to attempt to fund operations and reduce its substantial debt load. The overall growth and income profile depicts a micro-cap biotech or medical device firm that is currently in a distressed phase, characterized by declining revenue, negative cash flows, and zero dividend distribution, relying entirely on operational efficiency gains or new product approvals to reverse its financial trajectory.